A novel formulation of the prostate cancer drug abiraterone acetate — currently marketed as Zytiga — will dramatically improve the quality of life for people suffering from prostate cancer, as pre-clinical trials by the University of South Australia show the new formulation improves the drug’s effectiveness by 40 per cent. Developed by Professor Clive Prestidge’s Nanostructure and Drug Delivery research group at UniSA’s Cancer Research Institute, the breakthrough discovery uses an oil-based oral formulation that not only enables a smaller dose of the drug to be effective, but also has the potential to dramatically reduce possible side effects, such as joint swelling and diarrhea.
To learn more about this discovery, click here.